Details for New Drug Application (NDA): 203007
✉ Email this page to a colleague
NDA 203007 describes LAPATINIB DITOSYLATE, which is a drug marketed by Natco Pharma Ltd and Teva Pharms Usa Inc and is included in two NDAs. It is available from one supplier. Additional details are available on the LAPATINIB DITOSYLATE profile page.
The generic ingredient in LAPATINIB DITOSYLATE is lapatinib ditosylate. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the lapatinib ditosylate profile page.
The generic ingredient in LAPATINIB DITOSYLATE is lapatinib ditosylate. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the lapatinib ditosylate profile page.
Summary for 203007
| Tradename: | LAPATINIB DITOSYLATE |
| Applicant: | Natco Pharma Ltd |
| Ingredient: | lapatinib ditosylate |
| Patents: | 0 |
Pharmacology for NDA: 203007
| Mechanism of Action | Protein Kinase Inhibitors |
Suppliers and Packaging for NDA: 203007
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LAPATINIB DITOSYLATE | lapatinib ditosylate | TABLET;ORAL | 203007 | ANDA | Lupin Pharmaceuticals, Inc. | 68180-801 | 68180-801-36 | 150 TABLET in 1 BOTTLE (68180-801-36) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 250MG BASE | ||||
| Approval Date: | Sep 29, 2020 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
